Evidence map›Paper›PMID 24829761›Full record

ArticleJournal for immunotherapy of cancer2014

Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.

Michael R Olin, Walter Low, David H McKenna, Stephen J Haines, Tambra Dahlheimer, David Nascene, Michael P Gustafson, Allan B Dietz, H Brent Clark, Wei Chen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. The CD14Frontiers in immunology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Michael R OlinDepartment of Pediatrics and the Masonic Cancer Center, University of Minnesota, 3-136 CCRB, 2231 6th St SE, Minneapolis, MN 55455, USA.
Walter LowDepartment of Neurosurgery, University of Minnesota, 2001 6th St SE, Rm 4-216, Minneapolis, MN 55455, USA.
David H McKennaDepartment of Laboratory Medicine and Pathology, University of Minnesota, 8609B, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Stephen J HainesDepartment of Radiology, University of Minnesota, 8292A, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Tambra DahlheimerDepartment of Laboratory Medicine and Pathology, 200 First St, Mayo Clinic, Rochester, MN 55901, USA.
David NasceneDepartment of Radiology, University of Minnesota, 8292A, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Michael P GustafsonDepartment of Laboratory Medicine and Pathology, 200 First St, Mayo Clinic, Rochester, MN 55901, USA.
Allan B DietzDepartment of Laboratory Medicine and Pathology, 200 First St, Mayo Clinic, Rochester, MN 55901, USA.
H Brent ClarkDepartment of Laboratory Medicine and Pathology, University of Minnesota, 8609B, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Wei ChenDepartment of Pediatrics and the Masonic Cancer Center, University of Minnesota, 3-136 CCRB, 2231 6th St SE, Minneapolis, MN 55455, USA.
Bruce BlazarDepartment of Pediatrics and the Masonic Cancer Center, University of Minnesota, 3-136 CCRB, 2231 6th St SE, Minneapolis, MN 55455, USA.
John R OhlfestDepartment of Pediatrics and the Masonic Cancer Center, University of Minnesota, 3-136 CCRB, 2231 6th St SE, Minneapolis, MN 55455, USA.
Christopher MoertelDepartment of Pediatrics and the Masonic Cancer Center, University of Minnesota, 3-136 CCRB, 2231 6th St SE, Minneapolis, MN 55455, USA.
University of Minnesota · US

Funding

GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
NCI NIH HHS R01 CA072669
6 · The paper itself

Abstract

backgroundWe tested the hypothesis that a novel vaccine developed from autologous dendritic cells (DC) loaded with cells from a unique allogeneic brain tumor cell line (GBM6-AD) would be well-tolerated and would generate an immune response.

methodPatients with recurrent primary brain tumors underwent vaccination with GBM6-AD/DC vaccine. Subjects were treated at escalating DC cell doses: 5 × 10(6) (one patient), 10 × 10(6) (one patient) and 15 × 10(6) (6 patients). Subcutaneous injections were planned for days 0, 14, 28, 42, 56, and monthly thereafter. The primary endpoint was the safety of the GBM6-AD/DC vaccination. The secondary endpoints were immune response, measured by flow cytometry, and the clinical outcome of tumor response defined by time to progression and overall survival.

resultsEight patients were treated. The first three patients were treated in the dose escalation phase of the trial; the remaining five patients received the maximum dose of 15 × 10(6) DC. No dose limiting toxicity was observed. The best response per modified McDonald criteria was partial response in one patient. Flow cytometric immune profiling revealed significant differences in CD4(+)IL17(+) lymphocytes and myeloid derived suppressor cell populations between patients characterized as having stable vs. non-stable disease.

conclusionThis first-in-human study shows that the GBM6-AD/DC vaccine was well tolerated and was associated with an immune response in a subset of patients. No MTD was achieved in this trial. This small-scale pilot provides information for larger scale investigations into the use of this allogeneic vaccine source.

Indexed as

Brain tumorDendritic cellImmunotherapyVaccine

Identifiers

PMID24829761
PMCPMC4019901
OpenAlexW2065148109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.